Enhanced Bioavailability and Targeted Delivery of Mesalamine for Crohn’s Disease Using Microemulsion Formulations

This study evaluates mesalamine-loaded microemulsions designed to enhance drug bioavailability and site-specific delivery in the gastrointestinal (GI) tract, targeting the treatment of Crohn's disease. Mesalamine, an anti-inflammatory drug, is conventionally limited by poor solubility and inconsistent site-specific action. This research examines various microemulsion formulations to improve mesalamine delivery to the colon, assessing parameters such as stability, droplet size, encapsulation efficiency, and pH-controlled release. Optimal formulations demonstrated controlled, targeted release in colonic conditions, high stability, and minimized premature drug release in nontarget GI regions. These findings suggest potential clinical applications for advanced mesalamine therapies in Crohn's disease management.